US Budget Impact Model for Selinexor in Relapsed or Refractory Multiple Myeloma

Jan Bassali, 1 Ian Gopal Gould, 2 James A Kaye, 3 Deirdre Mladsi, 4 Jyotsna Mehta 5 1Global Medical and Scientific Affairs Department , Karyopharm Therapeutics, Newton, MA, 02459, USA; 2Research Health Economy, RTI Health Solutions, Research Triangle Park, NC 27709-2194, USA; 3Epidemiology, RTI H...

Full description

Bibliographic Details
Main Authors: Bassali J, Gould IG, Kaye JA, Mladsi D, Mehta J
Format: Article
Language:English
Published: Dove Medical Press 2020-06-01
Series:ClinicoEconomics and Outcomes Research
Subjects:
Online Access:https://www.dovepress.com/us-budget-impact-model-for-selinexor-in-relapsed-or-refractory-multipl-peer-reviewed-article-CEOR